VSIR and non-small cell lung carcinoma: For example, HMBD-002, a novel anti-VISTA IgG4 monoclonal antibody, has demonstrated strong preclinical efficacy as monotherapy and in combination with pembrolizumab, significantly inhibiting tumor growth in TNBC and NSCLC models [302]​.